Cancer - Advances, Knowledge, Integrative & Holistic Treatments
19.4K views | +0 today
Follow
Cancer - Advances, Knowledge, Integrative & Holistic Treatments
Your new post is loading...
Your new post is loading...
Scooped by Graham Player Ph.D.
Scoop.it!

F.D.A. Allows First Use of a New Cancer Drug

F.D.A. Allows First Use of a New Cancer Drug | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
The treatment unleashes the body’s immune system against tumors, and will initially be used against advanced melanoma.
Graham Player Ph.D.'s insight:

This is a new class of cancer drugs that unleashes the body’s immune system to fight tumors.

Tumors activate brakes on the immune system, preventing it from attacking them. Keytruda is the first drug approved that inhibits the action of one of those brakes, a protein known as PD-1, or programmed death receptor 1.

more...
No comment yet.
Scooped by Graham Player Ph.D.
Scoop.it!

iPhone App That Detects Skin Cancer

iPhone App That Detects Skin Cancer | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
The DermoScreen app, developed in Houston, works with a dermoscope attachment. The lens scans unusual looking lesions and highlights at-risk patients.
Graham Player Ph.D.'s insight:

An app for the iphone has been developed to detect skin cancer, and is now being evaluated at the University of Texas MD Anderson Cancer Centre.

Early testing has found the device to be accurate 85% of the time. This is more accurate than family doctors who were found to have an accuracy average of 50% to 70%. Specialist dermatologists typically have an accuracy rate of 90%.

The app relies on the connection of a special magnifying lens attached to the iphone.

more...
Tambre Leighn's curator insight, May 24, 2014 3:37 PM

Putting more control into the hands of individuals...technology that may eventually help people take responsibility and have more opportunity to save their own lives.  Looking forward to hearing outcomes of the current testing at MD Anderson!

Scooped by Graham Player Ph.D.
Scoop.it!

Closer to a Cure for Skin Cancer

Closer to a Cure for Skin Cancer | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
The new treatment, which will bring hope to hundreds of thousands of people in Britain with terminal conditions, involves the combination of two different types of drug that 'reboot' the immune system.
Graham Player Ph.D.'s insight:

A new treatment for skin cancer which combines two drugs that help to ‘reboot’ the immune system is showing positive encouraging effects in seriously ill melanoma patients.

One of the drugs, ipilimumab, was approved by the FDA in March 2011 to treat patients with late-stage melanoma that has spread or cannot be removed by surgery. According to research presented to the European congress in Amsterdam just a few days ago, 17% of patients are cured by this drug alone.

Another class of immunotherapy drugs known as anti- PD1 drugs has been shown to block activity of the programmed death 1 (PD-1) molecule, an immune checkpoint receptor found on T cells. T cells fight infections in our bodies and also facilitate the body’s attack on tumors. The PD-1 molecule on T cells interacts with another molecule, the programmed death 1 ligand (PD-L1) that fits with PD-1 like a lock and key. This interaction helps to modulate the immune response of T cells to various stimuli, including infections. PD-L1 is found on cells throughout the body, but tumor cells can also express PD-L1, resulting in a dampened response of the immune system to the tumor. Anti-PD1 antibodies block the interaction between PD1 and PD-L1 to boost T-cell activity in response to tumors.

Initial trials have shown that combining ipilimumab with anti-PD1 drugs produces ‘spectacular levels of tumor shrinkage’ according to Dr James Larkin, of the Royal Marsden Hospital in London. Initial trial results presented earlier this year showed that tumors shrank by more than half in 11% of patients put on ipilimumab, in 41% put on anti-PD1s – but in 53% of those given both.

more...
No comment yet.
Scooped by Graham Player Ph.D.
Scoop.it!

Skin Cancer Survival Rates in Scotland at All-Time High

Skin Cancer Survival Rates in Scotland at All-Time High | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
Eight out of 10 men and nine out of 10 women, diagnosed with the most dangerous form of skin cancer will survive the disease, says a new report.
Graham Player Ph.D.'s insight:

Skin cancer survival 30 years ago was only 58% of men and 78% of women. Today it is 80% and 90%, due to better treatment, early diagnosis and awareness of symptoms.

more...
Noah Butler's curator insight, November 12, 2014 1:48 AM

This article is about how skin cancer rates in Scotland are at an all time high and explains how this has happened due to better prevention and scientific research that has made this possible. This article relates to what we have been doing in class because we have recently talked and have been taught about lifestyle diseases and skin cancer fits into this category. As a class we have looked at the signs and symptoms of skin cancer and also how to prevent skin cancer. In my opinion I believe this a good article because again it talks about the positives and the success that has come out of Scotland about the survival rates and it is much better than all of the negative talk that has been discussed and talked about for a very long time.

Scooped by Graham Player Ph.D.
Scoop.it!

New Skin Cancer Drugs Approved

New Skin Cancer Drugs Approved | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
SILVER SPRING, Md. -- Two new drugs for metastatic or inoperable melanoma, dabrafenib (Tafinlar) and trametinib (Mekinist), were approved by the FDA on Wednesday.
Graham Player Ph.D.'s insight:

The FDA has just approved two new drugs for melanomas that have spread.

The drugs are dabrafenib (Tafinlar) and trametinib (Mekinist) which target BRAF V600E mutations that occur in about half of melanoma tumors. Dabrafenib is an inhibitor of the BRAF gene when it carries the so-called V600E mutation. Trametinib inhibits a target known as MEK and is effective primarily against melanomas carrying either the V600E or V600K mutations.

The drugs were approved as standalone drugs for use separately and not together. Based on a trial in 250 patients, dabrafenib prolonged progression-free survival by 2.4 months. In a trial of 322 patients trametinib prolonged progression-free survival by 3.3 months. Both of the drugs come with a list of side-effects.

more...
No comment yet.
Scooped by Graham Player Ph.D.
Scoop.it!

41% Increase in Skin Cancer Referrals in the UK

41% Increase in Skin Cancer Referrals in the UK | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
The number of people in England admitted to hospital for skin cancer has risen by 41 per cent in the past five years, but much of the increase is due to a change in GP practice, scientists said.
Graham Player Ph.D.'s insight:

In the UK over the past 5 years there has been a 30% increase in the hospital admissions for melanoma, the most serious type of skin cancer, and a 43% increase in admissions for non-melanoma skin cancer.

It is believed there has been two main factors to cause this - increasing sun exposure, and more patients referred to hospitals rather than being treated in a doctor’s surgery.

more...
No comment yet.
Scooped by Graham Player Ph.D.
Scoop.it!

Viagra May Increase Risk of Skin Cancer

Viagra May Increase Risk of Skin Cancer | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
AFP-Getty Images fileResearchers found that men who took Viagra were about 84 percent more likely to develop melanoma than men who didn’t.Men who use Viagra ...
Graham Player Ph.D.'s insight:

A preliminary study, by Warren Alpert Medical School at Brown University, of 26,000 men found that men who took sildenafil (best known as Viagra) were 84% more likely to develop melanoma than men who didn’t take the drug.

Viagra may increase the risk of melanoma because it affects the same genetic pathway that allows the skin cancer to become more invasive, according to Dr. Abrar Qureshi, professor and chair of the dermatology department and co-author of the study.

more...
No comment yet.
Scooped by Graham Player Ph.D.
Scoop.it!

New Target For Melanoma Treatment

New Target For Melanoma Treatment | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
A new target for melanoma treatment is an essential gene for metastasis
Graham Player Ph.D.'s insight:

Ze’ev Ronai, Ph.D., scientific director of Sanford-Burnham Medical Research Institute at La Jolla, and his team as well as collaborators at Yale University, show that without PDK1 expression, melanoma tumors were smaller in size, had a significant loss of metastasis, and a prolonged survival—in some cases survival time was increased to over 50 percent— in other cases melanoma was completely prevented.

The PDK1 gene was previously known to play an important role in normal cell processes, such as metabolism, protein translation, and cell survival under stress conditions. PDK1 was also implicated in some types of cancer, such as pancreatic cancer, but not others, such as non-small cell lung cancer. This is the first study that shows the negative role that PDK1 expression plays in melanocytes (cells that will transform to melanoma).

more...
No comment yet.
Scooped by Graham Player Ph.D.
Scoop.it!

Skin Cancer on the Rise in Young Women

Skin Cancer on the Rise in Young Women | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it
Friends and colleagues were surprised to see the scar on my face because I was only 28. Even the medical resident who attended my surgery said I was the youngest skin cancer patient she had met.
Graham Player Ph.D.'s insight:

A recent study by the Mayo Clinic found that melanoma, the most serious type, had increased eightfold for women under 40 since 1970.

more...
No comment yet.
Rescooped by Graham Player Ph.D. from Breast Cancer News
Scoop.it!

FDA Approves New Drug For Lymph Node Mapping

FDA Approves New Drug For Lymph Node Mapping | Cancer - Advances, Knowledge, Integrative & Holistic Treatments | Scoop.it

"The Food and Drug Administration has approved Lymphoseek (technetium Tc 99m tilmanocept) Injection—a receptor targeted radiopharmaceutical—for use in patients with breast cancers or melanomas who are undergoing surgery to remove tumor-draining lymph nodes to help doctors locate lymph nodes."


Via Curated by A4BC.ORG
Graham Player Ph.D.'s insight:

This imaging drug is the first new drug used for lymph node mapping to be approved in more than 30 years.

more...
Curated by A4BC.ORG's curator insight, April 4, 2013 2:17 PM

Lymphoseek, a "recepter targeted radiopharmaceutical", is used in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma. It was approved by the FDA in March.